Welcome to our dedicated page for Jade Biosciences SEC filings (Ticker: JBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Jade Biosciences filings document a Nasdaq-listed clinical-stage biotechnology issuer developing antibody therapies for autoimmune diseases. Form 8-K reports furnish operating and financial results and attach corporate updates covering JADE101, JADE201, JADE301, research progress, and liquidity-related disclosures.
The company's proxy and material-event filings cover annual meeting matters, board and officer changes, compensatory arrangements, employment inducement stock plans, material agreements, private placement securities, common stock and pre-funded warrant terms, and other capital-structure disclosures. The filings also identify Jade as an emerging growth company with common stock registered under the Exchange Act.
Jade Biosciences reported interim Phase 1 results for JADE101, its investigational anti‑APRIL antibody for IgA nephropathy. In 32 healthy volunteers given single subcutaneous doses from 175 mg to 1,400 mg, JADE101 showed a favorable safety profile, with only mild to moderate treatment‑emergent events and no severe adverse events or discontinuations.
A 700 mg dose produced prolonged IgA reductions of about 70% sustained at 12 weeks, with pharmacokinetic modeling suggesting this effect could be maintained using a 350 mg maintenance dose every 12 weeks. JADE101 demonstrated ultra‑high APRIL binding affinity, rapid and sustained free APRIL suppression, and an estimated half‑life of 24.2 days.
Jade has initiated JUNIPER, a Phase 2 open‑label IgA nephropathy trial in roughly 30 participants using a 700 mg induction dose followed by 350 mg maintenance every 8 or 12 weeks, with interim data anticipated in 2027. A registrational Phase 3 trial is planned for the first half of 2027, subject to FDA requirements. The company reports $311 million in cash, cash equivalents and investments as of March 31, 2026, which it expects to fund operations into the first half of 2028.
Jade Biosciences, Inc. is registering 39,542,339 shares of Common Stock for resale by selling stockholders under a shelf prospectus. The Resale Shares include October 2025 PIPE shares and pre-funded warrants, December 2025 PIPE shares, shares issued in connection with Pre-Merger Financing, and shares issuable upon conversion of Series A Preferred Stock.
The company states it will not receive proceeds from resale by the selling stockholders, but will receive nominal cash exercise prices if certain pre-funded warrants are exercised for cash. The registration satisfies contractual registration rights under April, October and December 2025 registration rights agreements.
Janus Henderson Group plc reported beneficial ownership of 3,105,669 shares of Jade Biosciences, Inc., equal to 6.3% of the common stock. The filing states Janus Henderson holds shared voting and dispositive power over those shares and identifies Janus Henderson Biotech Innovation Master Fund Ltd. as holding more than 5%. The filing was signed on 5/15/2026.
Jade Biosciences, Inc. filed a shelf resale registration covering 39,542,339 shares of common stock for resale by selling stockholders. The prospectus lists specific blocks from PIPE financings, pre-funded warrants and conversions of Series A Preferred Stock. The company will not receive proceeds from these resale transactions.
The filing states 49,316,287 shares outstanding as of March 15, 2026 for calculation purposes and discloses a last reported Nasdaq sale price of $25.26 per share (May 5, 2026). The registration satisfies contractual registration rights dated April, October and December 2025.
Jade Biosciences, Inc. filed a shelf registration to offer up to $600,000,000 of securities, including an at-the-market sales agreement to sell up to $200,000,000 of Common Stock through Jefferies LLC. The prospectus covers Common Stock, Preferred Stock, Debt Securities, Warrants and Units.
The prospectus describes an at-the-market program under a Sales Agreement dated May 7, 2026, Jefferies’ compensation up to 3.0% of gross proceeds, and incorporates risk factors and prior SEC filings by reference. Shares outstanding were 49,345,967 as of March 31, 2026.
Jade Biosciences, Inc. (JBIO) filed a prospectus supplement to update its Form S-1 with information from its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026. The company reported a net loss of $40.4 million for the quarter and used $24.1 million of cash in operations. Cash and cash equivalents were $55.1 million and investments were $256.2 million, totaling $311.3 million as of March 31, 2026. Shares outstanding were 49,359,875 as of May 1, 2026. The prospectus supplement also discloses an Open Market Sales Agreement entered May 7, 2026, under which the company may sell up to $200.0 million of common stock in at‑the‑market offerings (the company has not sold any shares under that agreement to date).
Jade Biosciences, Inc. files a prospectus supplement to its Form S-1 to update the offering document with information from its Form 10-Q for the quarter ended March 31, 2026. The supplement relates to Common Stock offered by selling stockholders and references a recent May 7, 2026 Form 10-Q.
The 10-Q discloses cash and cash equivalents of $55.1 million, investments of $256.2 million (totaling $311.3 million), a net loss of $40.4 million for the three months ended March 31, 2026, and 49,359,875 shares outstanding as of May 1, 2026. The supplement updates risk and operational disclosures and attaches the quarterly financial statements.
Jade Biosciences, Inc. reported a larger quarterly loss as it ramps up autoimmune drug development. For the three months ended March 31, 2026, the company recorded a net loss of $40.4 million, compared with $38.2 million a year earlier, driven mainly by higher research and development spending.
Research and development expenses rose to $36.1 million, and general and administrative costs increased to $7.4 million as Jade expanded its organization and pipeline. Operating cash outflow was $24.1 million in the quarter.
The balance sheet remains strong, with $55.1 million in cash and cash equivalents and $256.2 million in investments, totaling $311.3 million of liquid resources as of March 31, 2026. Management believes this will fund operating and capital needs for at least twelve months from the financial statement issuance date.
Jade is advancing three biologic candidates: JADE101 for IgA nephropathy, JADE201 for rheumatoid arthritis and other autoimmune diseases, and JADE301 targeting an undisclosed pathway, with multiple Phase 1 and Phase 2 trials expected to start or deliver interim data between 2026 and 2027.